Total Q2 2025 sales GBP 8.0 billion +1% AER; +6% CER. Emma Walmsley, Chief Executive Officer, GSK (GSK) said, “GSK’s strong momentum in 2025 continues with another quarter of excellent performance driven mainly by Specialty Medicines, our largest business, with double-digit sales growth in Respiratory, Immunology & Inflammation, Oncology and HIV. We also continue to make very good progress in R&D, with 3 major FDA approvals achieved so far this year, 16 assets now in late-stage development, and 4 more promising medicines to treat cancer, liver disease and HIV expected to enter Phase III and pivotal development by the end of the year. With all this, we now expect to be towards the top end of our financial guidance for 2025 and remain confident in our long-term outlooks.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GSK:
- GSK’s Belimumab Study: A Potential Game-Changer for Early SLE Treatment
- Trump administration mulls charging patent holders 1%-5% fee, WSJ reports
- GSK’s Long-Term Study on Atopic Dermatitis Drug: A Potential Game Changer?
- GSK’s Promising Phase 3 Study on Belimumab for ILD: Key Insights for Investors
- GSK’s Innovative Hepatitis B Treatment Study: A Potential Game-Changer?